entertainment -WSS

entertainment

author：entertainment 2025-09-30 17:04:18 - browse：54

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： FDA approves updated Covid vaccines

WSS

Generate Biomedicines machine learning biotech raises $273M

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

How medical schools plan to diversify without affirmative action

New Covid vaccine is recommended for everyone 6 months or older

Caribou posts encouraging results on off

Stanford president’s abrupt resignation sparks debate

focus

entertainment

leisure time

Sports medicine is finally prioritizing gender equality

There’s a way to spot data fakery. All journals should be using it

Hepatitis C has a cure — but many Americans still lack access to it

'CMA Fest' 2023: How to watch, who is performing and more

Trump demands the U.S. pay no more for drugs than other countries … again

Scientists grapple with ethics of stem cell research

Anesthesiologist group: stop taking Ozempic before surgery

How a Boston hospital is priming medical residents to use GPT

Drug repurposing or repositioning? The language matters

IRA could hurt research into orphan drugs for rare diseases

focus

'CMA Fest' 2023: How to watch, who is performing and more

Long Covid needs a new name — and a new frame

New weight loss drugs vying to be the next Wegovy or Mounjaro

How housing is health care on Long Island

Mystery swirls around US soldier who entered North Korea days ago, officials say

Popular nasal decongestant doesn't actually relieve congestion

hotspot

leisure time

Wikipedia

explore